

Frailty and Depression in Late Life

Patrick J. Brown, PH.D

Assistant Professor of Clinical Psychology in Psychiatry
College of Physicians and Surgeons, Columbia University
New York State Psychiatric Institute


Disclosures

- No financial interests to disclose
- Data for this presentation were supplied by:
 - Nordic Research on Ageing study (NORA)
 - Health Aging and Body Composition Study (NIA)
- Funding from this presentation:
 - National Institute of Mental Health (K23)

Major Depressive Disorder

- Depressed Mood OR Loss of interest or pleasure
- And four of the following:
 - Significant weight loss/gain (+ 5% of body weight in a month)
 - Insomnia or hypersomnia
 - Psychomotor agitation/retardation
 - Fatigue or loss of energy
 - Feeling worthless or guilty
 - Difficulty concentrating
 - Recurrent thoughts of death
- Clinically significant functional impairment

Lifetime prevalence of MDD: NCS-R



Kessler et al. *Arch Gen Psych* (2005)


Depression in late life

- 3-7% of adults over the age of 65 have a dx of MDD
 - 15% have significant but subthreshold symptoms
 - One of the leading causes of disability and functional impairment in the world
 - Highest rate of successful suicide attempts
 - Older white men (strong correlation with recent visits to doctor)
 - Under recognized and hence under treated
 - DSM system not created with late life in mind
 - Geriatric Depression Scale
 - Created to remove somatic items (concentration issues, fatigue, sleep deficits) that may have multiple etiologies and not be due to depression per se

Causal attributions of symptoms by age: Appetite loss


Age 18 – 39

Total symptom endorsement:
22.4%




Age 40 – 59

Total symptom endorsement:
24.6%



Age 60+

Total symptom endorsement:
19.3%




■ Psychiatric

■ Illness/injury or
drugs/alcohol/medication

Causal attributions of symptoms by age: Fatigue


Age 18 – 39

Total symptom
endorsement:
11.8%




Age 40 – 59

Total symptom
endorsement:
10.3%



Age 60+


Total symptom
endorsement:
10.2%



- Psychiatric
- Illness/injury or
drugs/alcohol/medication


Mezuk & Eaton *Handbook of Measurement* (2010)

Depression without sadness?



From Gallo, Anthony & Muten (1994)

Comparison of response rates in placebo controlled trials of antidepressant medications



Identifying characteristics in late life depression

- May identify different etiologies, resulting in different treatment strategies targeting different mechanisms
 - For example:
 - Executive dysfunction
 - Tests: Trail-making Test A/B, Stroop, Matrix Reasoning, Digit Symbol
 - Marks what is called a vascular depression
 - Associated with vascular diseases/risk factors including HTN, DM, smoking, obesity
 - Increased white matter hyperintensity burden
 - Attenuated response to antidepressant medications


Frailty and depression in late life

- Physical System: Somatic characteristics of depression phenomenologically similar to frailty
 - Psychomotor slowing – slow gait
 - Low energy – fatigue
 - Decreased physical activity – Decreased physical activity
 - Weight loss – weight loss
- Are frailty and depression separate constructs or merely different manifestations of the same underlying syndrome?

Why is frailty important in the context of late life depression?

- 10 years ago, Ira Katz introduced the concept of frailty in geriatric psychiatry. He concluded:
 - “The parallels between depression and frailty are readily apparent. Depending on the definitions used, it is possible to make a case for each of these conditions as a cause, consequence, or comorbidity of the other. It is also possible to argue for their congruence; within limits, they may be different labels for the same syndrome. However, certain conclusions are not merely semantic. Multidisciplinary research on depression and frailty will be necessary to advance knowledge of mechanisms and interventions for both.”
- Inflammation as common underlying mechanism?

Correlated but distinct constructs




Overlapping constructs

- Among those classified as not depressed (77% of respondents)
 - 5.9% were classified as frail
- Among those classified as moderately depressed (20% of respondents)
 - 69.0% were classified as frail
- Among those classified as severely depressed (3% of respondents)
 - 100% were classified as frail

Behavioral Changes During the First 12 weeks of High Dose IFN-alpha for Malignant Melanoma

| | Percent |
|---------------------------------|---------|
| Depressive Symptoms | |
| Depressed mood | 60 |
| Anhedonia | 30 |
| Suicidal Thoughts | 10 |
| Feelings of Guilt | 5 |
| Anxious Symptoms | |
| Tension/Irritability | 50 |
| Anxious Mood | 45 |
| Fear | 15 |
| Cognitive Symptoms | |
| Loss of Concentration | 30 |
| Memory Disturbances | 15 |
| Word-finding Problems | 15 |
| Episodes of Confusion | 10 |
| Indecisiveness | 10 |
| Neurovegetative Symptoms | |
| Fatigue/ Loss of Energy | 80 |
| Abnormal Sleep | 45 |
| Psychomotor Retardation | 40 |
| Abnormal Appetite | 35 |
| Somatic Symptoms | |
| Pain | 55 |
| Gastrointestinal Symptoms | 50 |

Development of Major Depression During IFN-alpha



Musselman et al., *NEJM*, 344:961-966, 2001.

Capuron et al., *Neuropsychopharmacology*, 26:643-652, 2002.

Felger, AAGP 2014

The Depressed-Frail Phenotype: High Risk Clinical Population

Clinical trajectory of the depressed-frail phenotype

- To identify salient characteristics of frailty that increase risk of death in depressed elders.
 - Nordic Research on Ageing Study (NORA)
 - 1027 75 year old men (n=436) and women (n= 591)
 - Mortality data extending out 12 years
- Depression (3 categories via CES-D)
 - More women, slowed processing speed, greater executive dysfunction, greater IADL impairment
 - Frailty
 - Slower Gait speed via 10-m walk (m/s)
 - Greater weakness via handgrip strength (kgf)
 - Greater levels of fatigue via Avlund Mob-T Scale
 - Lower physical activity levels via self-report

Depression and frailty


Combined models of frailty characteristics

| | No Depression (n = 543) Hazard ratio (95% CI) | | Depression (n = 261) Hazard ratio (95% CI) | |
|---------------------------------|--|--------------------------------|---|--------------------------------|
| | Men (n=278) | Women (n=265) | Men (n=84) | Women (n=177) |
| Frailty | | | | |
| Low Activities Yes vs. No | 1.76 (1.17, 2.65) ^a | 1.34 (0.78, 2.28) | 1.68 (0.76, 3.74) | 1.56 (0.93, 2.61) |
| Exhaustion Yes vs. No | 1.51 (1.00, 2.28) | 1.54 (0.92, 2.56) | 1.48 (0.69, 3.15) | 1.94 (1.11, 3.40) ^a |
| Slow Gait Speed Yes vs. No | 1.54 (1.05, 2.26) ^a | 1.30 (0.79, 2.14) | 1.52 (0.67, 3.45) | 1.84 (1.05, 3.21) ^a |
| Low Grip Strength Yes vs. No | 1.02 (0.65, 1.59) | 1.83 (1.06, 3.18) ^a | 1.35 (0.64, 2.81) | 1.19 (0.70, 2.02) |

Cox regression models stratified by site and gender with one frailty characteristic entered into each model; results did not differ with comorbidities added



^a P < .05; ^b P < .01; ^c P < .001

Gait Speed x Gender x Depression




Mortality rates
Nondepressed Men:
 No gait: 48%
 Gait: 75%

Depressed Men:
 No gait: 45%
 Gait: 71%




Nondepressed Women:
 No gait: 26%
 Gait: 40%

Depressed Women:
 No gait: 32%
 Gait: 58%





Exhaustion x Gender x Depression




Mortality rates
Nondepressed Men:
 No exhaust: 48%
 Exhaust: 70%

Depressed Men:
 No exhaust: 45%
 Exhaust: 59%



Nondepressed Women:
 No exhaust: 30%
 Exhaust: 47%

Depressed Women:
 No exhaust: 33%
 Exhaust: 63%



Depressed-frail phenotype

- Questions:

1. How does the presence of frailty characteristics impact mortality in older adults with depression?
 - Depression enhanced the effect of slowed gait and exhaustion on mortality
 - But only in women?
2. Are there common physiological mechanisms that mark a particular manifestation of the phenotype?
 - Inflammation?

Health ABC: Inflammation, Gait, Depression, and Mortality

A longitudinal study of 3075 well-functioning African American and Caucasian adults aged 68-80 at the time of initial eval

The aims of this study were to:

1. Identify the trajectories of inflammation, depression, and slow gait and determine their association
2. Determine the order in which the conditions manifest
3. Investigate the individual and joint associations between mortality and trajectories for these conditions

Variables:

- Depression: CES-D \geq 10
- Slow Gait: $<$ 1.02 m/s
- Inflammation: Interleukin 6 $>$ 3.24 pg/mL



Analytic Tools:

- Multivariate Longitudinal Latent Class Growth Analysis
 - Uses all of the longitudinal data, models missing, thus less reliance on single point prevalence analyses (baseline values)

Health ABC: Latent Class Analysis

A. estimated probabilities for inflammation

B. estimated probabilities for slow gait




C. estimated probabilities for depression

Trajectories of inflammation associated with:

- slow gait $r = .40, P < .001$
- depression $r = .11, P < .001$

Trajectories of slow gait with:

- depression $r = .49, P < .001$




Trajectories of inflammation associated with:

- higher BMI, more vascular and cardiovascular diseases
- Slower gait, lower energy

Brown et al., in prep


HABC: Order of presentation



Incidence rates were examined to identify the order of presentation over 10-years in elders with increasing- or always-high-probability trajectories of inflammation, depression, and slow gait

Brown et al., in prep


HABC: Covariate Adjusted Mortality Rates



Main effect of trajectories of inflammation; two-way interaction between trajectories of slow gait and depression

Covariates adjusted for include baseline age, sex, body mass index, 3MS, baseline medical comorbidity (vascular disease, physical impairment, respiratory illness, cardiovascular disease, cerebrovascular disease, and malignant cancer), and baseline anti-inflammatory medication use.

HABC: Covariate Adjusted Mortality Rates




Main effect of trajectories of inflammation; two-way interaction between trajectories of slow gait and depression

Covariates adjusted for include baseline age, sex, body mass index, 3MS, baseline medical comorbidity (vascular disease, physical impairment, respiratory illness, cardiovascular disease, cerebrovascular disease, and malignant cancer), and baseline anti-inflammatory medication use.

Brown et al., in prep

Conclusions: Health ABC Study

- Inflammation, depression, and slow gait define a phenotype at grave risk of death
 - Trajectories of Inflammation has an independent effect on mortality after accounting for covariates
 - The effect of trajectories of slow gait on mortality depends on depression trajectory status
- Multiple pathways into phenotypic cycle
 - Most common are via inflammatory or mobility pathways
 - Depression appears to be a secondary process in late life



Implications and Future Directions

- Do specific frailty characteristics predict response to antidepressant treatment in older depressed patients?
 - If so, what is the underlying mechanism that identifies them?
 - Inflammation?
 - Slow gait: Dopamine fx in basal ganglia
 - Anhedonia, amotivation
 - Differentiate “I don’t feel like doing anything” and “I don’t have the energy to do anything”
 - Fatigue and its biological underpinnings
 - Differences may identify specific mechanisms to target via different intervention implementation
 - Exercise, anti-inflammatories, antidepressant medications, nutrition, problem solving and/or cognitive behavioral therapy

Acknowledgements

- Division of Geriatric Psychiatry, Columbia University, NYSPI
 - Steven Roose, MD
 - Bret Rutherford, MD
 - Jane Tandler
 - Davangere Devanand, MD
 - Joel Sneed, PhD
 - Justina Laurence Ray
- Nordic Research on Ageing Study
 - Taina Rantanen, PhD
 - Kirsten Avlund, PhD
- Health, Aging and Body Composition Study
 - Tamara Harris, MD
 - Anne Newman, PhD
 - Kristine Yaffe, MD
 - Hilsa Ayonayon, PhD
 - Meryl Butters, PhD
 - Suzanne Satterfield, MD Dr. P.H.
 - Eleanor Simonsick, PhD
- Virginia Commonwealth University
 - Briana Mezuk, PhD
- Emory University
 - Jennifer Felger, PhD